Revvity

US · RVTY #1032 by market cap Listed 1970

153.60 +0.30 +0.20%

Live - 5344 symbols - heartbeat 533s ago · 2026-10-08 07:09

Pre-market 152.80 -0.52%

After-hours 153.60 0.00%

Overnight 153.40 -0.13%

Market cap: 17.14B
P/E (TTM): 73.85
P/B: 2.37
EPS: 2.07
Div yield: 0.18%
52W pos: 85%

Reader sentiment Are you bullish or bearish on RVTY?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 3.21, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +3.67% YoY

Margins

Gross margin: 54.77%
Operating margin: 12.49%
Net margin: 8.45%

Key ratios & quality

Enterprise value: 19.47B
Altman Z-Score: 3.21

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2021	2022	2022	2023	2024	2025
Revenue	2.78B	2.88B	2.66B	3.83B	3.31B	2.75B	2.76B	2.86B
Gross profit	1.34B	1.40B	1.73B	2.43B	1.99B	1.54B	1.54B	1.56B
Selling & admin expenses	811.91M	815.32M	716.47M	975.19M	1.03B	1.02B	994.07M	991.89M
Research & development	194.00M	189.34M	146.44M	200.34M	221.62M	216.58M	196.84M	215.84M
Operating profit	335.03M	391.40M	867.27M	1.26B	742.70M	300.56M	346.74M	356.64M
Pretax profit	257.68M	237.14M	800.07M	1.20B	651.84M	182.98M	316.13M	268.28M
Tax	20.21M	9.39M	169.51M	314.15M	139.16M	3.47M	33.06M	28.39M
Net profit	237.93M	227.56M	727.89M	943.16M	569.18M	693.09M	270.39M	241.20M
Basic EPS	2	2	7	8	5	6	2	2
Diluted EPS	2.13	2.04	6.49	8.08	4.50	5.55	2.20	2.07

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
Revenue	664.76M	720.28M	698.95M	772.06M	711.12M	729.69M
Gross profit	375.55M	392.56M	374.60M	421.66M	387.66M	416.87M
Selling & admin expenses	249.72M	250.22M	241.91M	251.73M	253.88M	280.04M
Research & development	53.60M	53.27M	50.80M	58.18M	57.89M	48.97M
Operating profit	72.23M	89.07M	81.90M	111.75M	75.89M	87.85M
Pretax profit	52.38M	68.65M	55.69M	91.56M	49.99M	63.53M
Tax	10.71M	13.43M	8.46M	-4.21M	9.10M	10.05M
Net profit	42.24M	53.95M	46.65M	98.36M	40.72M	51.82M
Basic EPS	0	0	0	1	0	0
Diluted EPS	0.35	0.46	0.40	0.87	0.36	0.47

Balance sheet

Line item	2018	2019	2021	2022	2022	2023	2024	2025
Total current assets	1.23B	1.37B	2.24B	2.44B	3.29B	3.00B	2.35B	2.24B
Cash & ST investments	163.11M	191.88M	402.04M	603.32M	454.36M	1.60B	1.16B	919.86M
Inventory	338.35M	356.94M	514.57M	425.89M	405.46M	428.06M	367.59M	379.50M
Total assets	5.98B	6.54B	7.96B	15.00B	14.13B	13.56B	12.39B	12.17B
Total current liabilities	771.63M	762.83M	1.65B	1.21B	1.54B	1.45B	653.10M	1.33B
Short-term debt	14.86M	46.55M	421.28M	33.55M	502.15M	754.78M	23.82M	618.86M
Long-term debt	1.88B	2.06B	1.61B	4.98B	3.92B	3.18B	3.15B	2.63B
Total liabilities	3,390,567,000.00	3,724,740,000.00	4,224,823,000.00	7,859,309,000.00	6,746,979,000.00	5,691,926,000.00	4,725,604,000.00	4,918,051,000.00
Total equity	2.58B	2.81B	3.74B	7.14B	7.38B	7.87B	7.67B	7.25B
Retained earnings	2.60B	2.81B	3.51B	4.42B	4.95B	5.61B	5.85B	6.05B

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
Total current assets	2.32B	2.24B	2.14B	2.24B	2.13B	2.30B
Cash & ST investments	1.14B	991.85M	931.39M	919.86M	860.32M	1.02B
Inventory	381.31M	388.47M	379.92M	379.50M	387.51M	378.50M
Total assets	12.36B	12.36B	12.14B	12.17B	12.00B	12.05B
Total current liabilities	648.19M	671.81M	1.22B	1.33B	1.24B	1.28B
Short-term debt	242.00K	230.00K	583.84M	618.86M	575.83M	572.16M
Long-term debt	3.17B	3.21B	2.63B	2.63B	2.63B	2.63B
Total liabilities	4,723,594,000.00	4,806,621,000.00	4,763,056,000.00	4,918,051,000.00	4,813,851,000.00	4,817,076,000.00
Total equity	7.64B	7.56B	7.38B	7.25B	7.18B	7.23B
Retained earnings	5.88B	5.93B	5.96B	6.05B	6.09B	6.13B

Cash flow

Line item	2018	2019	2021	2022	2022	2023	2024	2025
Operating cash flow	311.04M	363.47M	892.18M	1.41B	679.81M	91.27M	628.30M	582.93M
Depreciation & amortization	180.59M	214.03M	201.65M	311.44M	427.00M	431.77M	427.85M	405.34M
Free cash flow	217.79M	282.14M	828.54M	1.32B	594.18M	9.90M	541.65M	509.41M
Dividends paid	-31.01M	-31.06M	-31.21M	-32.37M	-35.34M	-34.97M	-34.45M	-32.80M
Stock buybacks / issuance	-57.45M	-6.31M	30.73M	-73.07M	-80.64M	-388.88M	-369.58M	-820.82M
Ending cash balance	166.32M	191.89M	402.61M	619.34M	470.75M	914.37M	1.16B	921.03M

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
Operating cash flow	128.16M	134.32M	138.50M	181.96M	115.23M	191.94M
Depreciation & amortization	97.42M	102.78M	102.06M	103.08M	105.06M	102.04M
Free cash flow	112.17M	115.45M	120.00M	161.79M	95.46M	180.87M
Dividends paid	-8.43M	-8.28M	-8.13M	-7.96M	-7.84M	-7.81M
Stock buybacks / issuance	-153.59M	-293.91M	-205.03M	-168.29M	-86.50M	-15.99M
Ending cash balance	1.14B	992.99M	932.58M	921.03M	861.47M	1.02B

Returns & efficiency

Line item	2018	2019	2021	2022	2022	2023	2024	2025
ROE %	9.35	8.43	22.23	17.34	7.84	9.09	3.48	3.23
ROA %	3.94	3.64	10.04	8.22	3.91	5.01	2.08	1.96
ROIC %	6.65	6.04	13.96	11.11	5.33	6.01	2.54	2.73
5-year avg ROE %	10.19	10.31	12.71	13.98	13.04	12.98	11.99	8.20
EBIT margin %	11.69	10.43	25.27	27.27	22.82	10.24	14.97	12.62
FCF / sales %	7.84	9.78	21.54	25.87	17.94	0.36	19.66	17.84
Current ratio	1.60	1.80	1.36	2.01	2.13	2.07	3.60	1.68
Quick ratio	1.03	1.20	0.94	1.08	0.69	1.54	2.75	1.25
Debt / assets	31.65	34.52	27.88	34.40	32.52	29.97	26.84	27.93
LT debt / equity	72.60	78.56	48.14	71.80	55.44	42.05	43.07	38.33
Interest coverage	4.85	4.73	19.23	13.53	7.27	2.85	4.28	3.91
Revenue CAGR (3Y) %	9.69	10.88	5.67	11.28	4.72	1.08	-10.38	-4.82
Net income CAGR (3Y) %	3.85	-0.97	35.49	58.26	35.74	-1.62	-34.06	-24.89
FCF CAGR (3Y) %	-5.60	-4.00	49.22	82.54	28.18	-77.14	-25.78	-5.00

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
ROE %	3.70	3.70	3.10	3.23	3.23	3.21
ROA %	2.22	2.21	1.91	1.96	1.97	1.95
ROIC %	2.76	2.83	2.60	2.73	2.79	2.80
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	15.48	14.62	12.89	12.62	12.40	12.36
FCF / sales %	18.92	17.97	17.68	17.84	16.98	19.17
Current ratio	3.58	3.33	1.75	1.68	1.72	1.80
Quick ratio	2.71	2.46	1.32	1.25	1.25	1.36
Debt / assets	26.90	27.30	27.75	27.93	27.93	27.74
LT debt / equity	43.54	44.66	37.76	38.33	38.63	38.31
Interest coverage	4.52	4.39	3.97	3.91	3.83	3.63
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

Diagnostics is the largest reported line at 50.84% of revenue, across 2 reported segments.
Life sciences follows at 49.16%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

Diagnostics50.84%

Life sciences49.16%

Quote time 2026-10-08 07:09:04 · For reference only, not investment advice and not tailored to your situation.